Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BASF Acquires Enzyme Maker Verenium

Biotechnology: Purchase by German giant ends roller-coaster ride for U.S. company

by Melody M. Bomgardner
September 27, 2013 | A version of this story appeared in Volume 91, Issue 39

BASF has agreed to buy enzyme maker Verenium for $62 million. The move adds an attractive product pipeline to BASF’s growing enzyme business while marking the end of the line for a once-high-flying player in the industrial enzyme field.

San Diego-based Verenium develops enzymes for industries such as animal nutrition, grain processing, and oil-field services. The firm has about 110 employees and posted sales last year of $57 million.

Verenium began life as Diversa, which sought microbes in extreme environments such as volcanoes and developed their enzymes for industrial uses. The company went public in 2000 and soared to a value of more than $5 billion. At its peak the firm had more than 350 employees. But investor interest in industrial biotechnology waned. By 2006, Diversa had shed employees and ended programs.

The following year, Diversa merged with the cellulosic ethanol developer Celunol to form Verenium. The firm reversed course in 2010, selling the ethanol business to BP and recasting itself as a specialty enzyme company. Last year, Verenium sold its business in oilseed-processing enzymes to DSM for $37 million.

For BASF, the purchase continues a buildup in enzymes. In May, it acquired Henkel’s detergent enzyme technology. It signed a licensing agreement with enzyme developer Dyadic International, and it expanded its collaboration with Direvo Industrial Biotechnology to develop enzymes for animal nutrition.

The acquisition strengthens BASF’s enzyme platform, according to Laurence Alexander, chemicals analyst at investment banking firm Jefferies. In a note to investors, Alexander pointed out that BASF will get a pipeline of products that have a $1.2 billion-per-year market opportunity.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.